Soluble receptor for advanced glycation end products alleviates nephritis in (NZB/NZW)F1 mice

Arthritis and Rheumatism

Volumn 65, Issue 7, 2013, Pages 1902-1912

  Lee, Sang Won ^a   Park, Kyu Hyung ^a   Park, Sungha ^a,b   Kim, Ji Hye ^a   Hong, Sung Yu ^a,b   Lee, Soo Kon ^a   Choi, Donghoon ^a,b   Park, Yong Beom ^a  

^a Yonsei University College of Medicine   (South Korea)

^b Yonsei University Health System   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; DOUBLE STRANDED DNA ANTIBODY; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN G2B; IMMUNOGLOBULIN G3; INTERCELLULAR ADHESION MOLECULE 1; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; VASCULAR CELL ADHESION MOLECULE 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY BLOOD LEVEL; ANTIGEN EXPRESSION; ARTICLE; DRUG EFFICACY; FEMALE; FLUORESCENCE ACTIVATED CELL SORTER; IMMUNE COMPLEX DEPOSITION; IMMUNOFLUORESCENCE; IMMUNOGLOBULIN BLOOD LEVEL; IN VITRO STUDY; IN VIVO STUDY; KIDNEY PARENCHYMA; LUPUS ERYTHEMATOSUS NEPHRITIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; T LYMPHOCYTE SUBPOPULATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIGEN-ANTIBODY COMPLEX; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; FEMALE; KIDNEY; LUPUS NEPHRITIS; MICE; MICE, INBRED NZB; MYCOPHENOLIC ACID; NF-KAPPA B; PREDNISOLONE; PROTEINURIA; RECEPTORS, IMMUNOLOGIC; TREATMENT OUTCOME;

EID: 84879846922     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.37955     Document Type: Article

References (44)

1. Ramasamy R, Vannucci SJ, Yan SS, Herold K, Yan SF, Schmidt AM,. Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration, and inflammation. Glycobiology 2005; 15: 16R-28R.
2. Goldin A, Beckman JA, Schmidt AM, Creager MA,. Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation 2006; 114: 597-605.
3. Bierhaus A, Humpert PM, Morcos M, Wendt T, Chavakis T, Arnold B, et al. Understanding RAGE, the receptor for advanced glycation end products. J Mol Med (Berl) 2005; 83: 876-86.
4. Park S, Yoon SJ, Tae HJ, Shim CY,. RAGE and cardiovascular disease. Front Biosci 2011; 16: 486-97.
5. Sims GP, Rowe DC, Rietdijk ST, Herbst R, Coyle AJ,. HMGB1 and RAGE in inflammation and cancer. Annu Rev Immunol 2010; 28: 367-88.
6. Sarkany Z, Ikonen TP, Ferreira-da-Silva F, Saraiva MJ, Svergun D, Damas AM,. Solution structure of the soluble receptor for advanced glycation end products (sRAGE). J Biol Chem 2011; 286: 37525-34.
7. Jin Q, Chen H, Luo A, Ding F, Liu Z,. S100A14 stimulates cell proliferation and induces cell apoptosis at different concentrations via receptor for advanced glycation end products (RAGE). PLoS One 2011; 6: e19375.
8. Kokkola R, Andersson A, Mullins G, Ostberg T, Treutiger CJ, Arnold B, et al. RAGE is the major receptor for the proinflammatory activity of HMGB1 in rodent macrophages. Scand J Immunol 2005; 61: 1-9.
9. Hou CH, Fong YC, Tang CH,. HMGB-1 induces IL-6 production in human synovial fibroblasts through c-Src, Akt and NF-κB pathways. J Cell Physiol 2011; 226: 2006-15.
10. Bagavant H, Fu SM,. Pathogenesis of kidney disease in systemic lupus erythematosus. Curr Opin Rheumatol 2009; 21: 489-94.
11. Maillard-Lefebvre H, Boulanger E, Daroux M, Gaxatte C, Hudson BI, Lambert M,. Soluble receptor for advanced glycation end products: a new biomarker in diagnosis and prognosis of chronic inflammatory diseases. Rheumatology (Oxford) 2009; 48: 1190-6.
12. Gordon C, Jayne D, Pusey C, Adu D, Amoura Z, Aringer M, et al. European consensus statement on the terminology used in the management of lupus glomerulonephritis. Lupus 2009; 18: 257-63.
13. Wang Y, Hu Q, Madri JA, Rollins SA, Chodera A, Matis LA,. Amelioration of lupus-like autoimmune disease in NZB/WF1 mice after treatment with a blocking monoclonal antibody specific for complement component C5. Proc Natl Acad Sci U S A 1996; 93: 8563-8.
14. Tesar V, Hruskova Z,. Treatment of proliferative lupus nephritis: a slowly changing landscape. Nat Rev Nephrol 2011; 7: 96-109.
15. Bertsias G, Ioannidis JP, Boletis J, Bombardieri S, Cervera R, Dostal C, et al. EULAR recommendations for the management of systemic lupus erythematosus: report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis 2008; 67: 195-205.
16. Abdulahad DA, Westra J, Bijzet J, Limburg PC, Kallenberg CG, Bijl M,. High mobility group box 1 (HMGB1) and anti-HMGB1 antibodies and their relation to disease characteristics in systemic lupus erythematosus. Arthritis Res Ther 2011; 13: R71.
17. Qing X, Pitashny M, Thomas DB, Barrat FJ, Hogarth MP, Putterman C,. Pathogenic anti-DNA antibodies modulate gene expression in mesangial cells: involvement of HMGB1 in anti-DNA antibody-induced renal injury. Immunol Lett 2008; 121: 61-73.
18. D'Agati V, Schmidt AM,. RAGE and the pathogenesis of chronic kidney disease. Nat Rev Nephrol 2010; 6: 352-60.
19. Clynes R, Herold K, Schmidt AM,. RAGE: exacting a toll on the host in response to polymicrobial sepsis and Listeria monocytogenes. Crit Care 2007; 11: 183.
20. Lee SW, Kim BS,. Comparison of therapeutic efficacy between bortezomib and combination treatment of prednisolone and mycophenolate mofetil on nephritis in NZB/WF1 mice. Clin Exp Rheumatol 2010; 28: 393-6.
21. Neubert K, Meister S, Moser K, Weisel F, Maseda D, Amann K, et al. The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat Med 2008; 14: 748-55.
22. Basta G, Lazzerini G, Massaro M, Simoncini T, Tanganelli P, Fu C, et al. Advanced glycation end products activate endothelium through signal-transduction receptor RAGE: a mechanism for amplification of inflammatory responses. Circulation 2002; 105: 816-22.
23. Biscetti F, Straface G, De Cristofaro R, Lancellotti S, Rizzo P, Arena V, et al. High-mobility group box-1 protein promotes angiogenesis after peripheral ischemia in diabetic mice through a VEGF-dependent mechanism. Diabetes 2010; 59: 1496-505.
24. Su Z, Sun C, Zhou C, Liu Y, Zhu H, Sandoghchian S, et al. HMGB1 blockade attenuates experimental autoimmune myocarditis and suppresses Th17-cell expansion. Eur J Immunol 2011; 41: 3586-95.
25. Schierbeck H, Lundback P, Palmblad K, Klevenvall L, Erlandsson-Harris H, Andersson U, et al. Monoclonal anti-HMGB1 (high mobility group box chromosomal protein 1) antibody protection in two experimental arthritis models. Mol Med 2011; 17: 1039-44.
26. Wendt T, Harja E, Bucciarelli L, Qu W, Lu Y, Rong LL, et al. RAGE modulates vascular inflammation and atherosclerosis in a murine model of type 2 diabetes. Atherosclerosis 2006; 185: 70-7.
27. Urbonaviciute V, Voll RE,. High-mobility group box 1 represents a potential marker of disease activity and novel therapeutic target in systemic lupus erythematosus. J Intern Med 2011; 270: 309-18.
28. Tian J, Avalos AM, Mao SY, Chen B, Senthil K, Wu H, et al. Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol 2007; 8: 487-96.
29. Avalos AM, Kiefer K, Tian J, Christensen S, Shlomchik M, Coyle AJ, et al. RAGE-independent autoreactive B cell activation in response to chromatin and HMGB1/DNA immune complexes. Autoimmunity 2010; 43: 103-10.
30. Ehlers M, Fukuyama H, McGaha TL, Aderem A, Ravetch JV,. TLR9/MyD88 signaling is required for class switching to pathogenic IgG2a and 2b autoantibodies in SLE. J Exp Med 2006; 203: 553-61.
31. Postol E, Meyer A, Cardillo F, de Alencar R, Pessina D, Nihei J, et al. Long-term administration of IgG2a anti-NK1.1 monoclonal antibody ameliorates lupus-like disease in NZB/W mice in spite of an early worsening induced by an IgG2a-dependent BAFF/BLyS production. Immunology 2008; 125: 184-96.
32. Liu Z, Bethunaickan R, Huang W, Ramanujam M, Madaio MP, Davidson A,. IFN-α confers resistance of systemic lupus erythematosus nephritis to therapy in NZB/W F1 mice. J Immunol 2011; 187: 1506-13.
33. Sthoeger ZM, Zinger H, Mozes E,. Beneficial effects of the anti-oestrogen tamoxifen on systemic lupus erythematosus of (NZB×NZW)F1 female mice are associated with specific reduction of IgG3 autoantibodies. Ann Rheum Dis 2003; 62: 341-6.
34. Zhu XM, Yao YM, Liang HP, Xu CT, Dong N, Yu Y, et al. High mobility group box-1 protein regulate immunosuppression of regulatory T cells through Toll-like receptor 4. Cytokine 2011; 54: 296-304.
35. Zhang Y, Yao YM, Huang LF, Dong N, Yu Y, Sheng ZY,. The potential effect and mechanism of high-mobility group box 1 protein on regulatory T cell-mediated immunosuppression. J Interferon Cytokine Res 2011; 31: 249-57.
36. Shi Y, Sandoghchian Shotorbani S, Su Z, Liu Y, Tong J, Zheng D, et al. Enhanced HMGB1 expression may contribute to Th17 cells activation in rheumatoid arthritis. Clin Dev Immunol 2012; 2012: 295081.
37. Xing Q, Wang B, Su H, Cui J, Li J,. Elevated Th17 cells are accompanied by FoxP3+ Treg cells decrease in patients with lupus nephritis. Rheumatol Int 2012; 32: 949-58.
38. Tucci M, Stucci S, Strippoli S, Silvestris F,. Cytokine overproduction, T-cell activation, and defective T-regulatory functions promote nephritis in systemic lupus erythematosus. J Biomed Biotechnol 2010; 2010: 457146.
39. Miyake K, Akahoshi M, Nakashima H,. Th subset balance in lupus nephritis. J Biomed Biotechnol 2011; 2011: 980286.
40. Tsukinoki T, Sugiyama H, Sunami R, Kobayashi M, Onoda T, Maeshima Y, et al. Mesangial cell Fas ligand: upregulation in human lupus nephritis and NF-κB-mediated expression in cultured human mesangial cells. Clin Exp Nephrol 2004; 8: 196-205.
41. Zheng L, Sinniah R, Hsu SI,. In situ glomerular expression of activated NF-κB in human lupus nephritis and other non-proliferative proteinuric glomerulopathy. Virchows Arch 2006; 448: 172-83.
42. Kalergis AM, Iruretagoyena MI, Barrientos MJ, Gonzalez PA, Herrada AA, Leiva ED, et al. Modulation of nuclear factor-κB activity can influence the susceptibility to systemic lupus erythematosus. Immunology 2009; 128: e306-14.
43. Martignoni M, Groothuis GM, de Kanter R,. Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opin Drug Metab Toxicol 2006; 2: 875-94.
44. Bucciarelli LG, Wendt T, Qu W, Lu Y, Lalla E, Rong LL, et al. RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation 2002; 106: 2827-35.